What sleep medication is appropriate for an older adult with coronary artery disease, hypertension, heart failure, and atrial fibrillation?

Sleep Medication for Older Adults with Multiple Cardiac Comorbidities

For an older adult with coronary artery disease, hypertension, heart failure, and atrial fibrillation, avoid benzodiazepines and Z-drugs (zolpidem, zaleplon, eszopiclone) entirely due to high risk of falls, fractures, cognitive impairment, and mortality in this population; instead, consider low-dose trazodone or mirtazapine as safer alternatives when insomnia requires pharmacologic intervention. 1

Primary Recommendation: Avoid Standard Hypnotics

The 2019 AGS Beers Criteria explicitly designates both benzodiazepines and nonbenzodiazepine hypnotics (Z-drugs) as high-risk medications to avoid in older adults, with strong recommendations and moderate-quality evidence. 1 The rationale includes:

• Increased mortality risk in older adults, particularly those with dementia 1
• Substantial fall and fracture risk, compounded by cardiovascular medications that may cause orthostatic hypotension 1
• Cognitive impairment and delirium, especially problematic in patients with atrial fibrillation on anticoagulation (fall-related bleeding risk) 1
• Motor vehicle crashes and physical dependence with minimal improvement in sleep latency 1
• Greater sensitivity in older adults to adverse effects even at low doses 1

The American Academy of Sleep Medicine (2017) gives only weak recommendations for eszopiclone, zolpidem, and zaleplon, acknowledging limited high-quality evidence and safety concerns. 2

Preferred Pharmacologic Approach

When non-pharmacologic interventions fail and medication is necessary:

Sedating Antidepressants (First Choice)

• Mirtazapine, nefazodone, or trazodone are preferred in cardiac patients because they lack the quinidine-like effects of tricyclic antidepressants that can worsen arrhythmias. 3
• These agents address insomnia while avoiding the dependence and fall risks of hypnotics. 3
• Trazodone is particularly useful at low doses (25-50 mg) for sleep without significant cardiac conduction effects. 3

Sedating Antipsychotics (Alternative)

• Melperone or low-dose quetiapine may benefit geriatric patients with chronic insomnia, though this is an off-label use. 3
• Exercise caution given the Beers Criteria warnings about antipsychotics increasing stroke risk and mortality in older adults with dementia. 1

Critical Cardiac Considerations

Atrial Fibrillation Concerns

• Sleep disruption and insomnia are increasingly recognized as contributing to AF pathogenesis and progression. 4
• Avoid medications that increase fall risk, as patients with AF are typically anticoagulated, making fall-related bleeding catastrophic. 1

Heart Failure Management

• Ensure optimal treatment of underlying heart failure, as untreated HF itself causes sleep disturbance. 5
• Screen for central sleep apnea, which is highly prevalent in heart failure patients and independently associated with mortality. 6
• Nocturnal hypoxemia from untreated sleep apnea increases sympathetic activity and worsens cardiovascular outcomes. 6

Drug Interactions

• Be vigilant about cytochrome P450 interactions between cardiac medications and any sleep agent prescribed. 3
• Patients on multiple cardiac drugs (beta-blockers, ACE inhibitors, diuretics, anticoagulants) have complex pharmacokinetic profiles. 3

Common Pitfalls to Avoid

• Do not prescribe Z-drugs thinking they are "safer benzodiazepines"—the Beers Criteria rates them equally problematic with the same adverse outcome profile. 1
• Do not use short-term benzodiazepines even briefly; rebound insomnia and rapid dependence occur in older adults. 1, 3
• Do not overlook sleep apnea screening; treating underlying OSA or central sleep apnea may resolve insomnia without hypnotics. 6, 4
• Avoid high-fat meals if eszopiclone is somehow deemed necessary despite guidelines, as absorption is delayed by approximately 1 hour. 2

Non-Pharmacologic Priority

Before any medication, address:

• Sleep hygiene optimization and cognitive behavioral therapy for insomnia (CBT-I) 2
• Evaluation for sleep-disordered breathing, given the patient's cardiac comorbidities 6, 4
• Optimization of heart failure therapy (SGLT2 inhibitors, MRAs, quadruple therapy) to reduce nocturnal dyspnea 5
• Review of current cardiac medications that may disrupt sleep (e.g., diuretics causing nocturia) 1